December 5th, 2024 – Shanghai, China. Aon Group, a leading global professional services firm, today announced it has released the China Best ESG Employers Award list for 2024. Hasten Biopharmaceutical Co., Ltd. (hereinafter referred to as Hasten) was awarded "2024 China Best ESG Employer Award" out of overall 186 companies.

On September 24, 2024, the 3rd Partner Exchange Conference hosted by Hasten Biopharmaceutical Co., Ltd. was grandly held in Shenzhen, Guangdong.

On Sept. 24, 2024, Hasten Biopharmaceutical Co., Ltd. and China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. signed a strategic agreement to deepen the comprehensive collaboration on further increasing branded drugs’ accessibility to Chinese patients.

On September 6th, 2024, representatives from Celltrion, a Korean biopharmaceutical company, visited the Shanghai Operations Management Center of Hasten Biopharmaceutical Co.,Ltd  (referred to as “Hasten”).

[June 28th, 2024] Hasten Biopharmaceutical Co., Ltd. (referred to as “Hasten”) announced today that it has successfully acquired the asset rights of 14 branded products across Pan-Asia countries and regions from Celltrion, a Korean biopharmaceutical company.

On May. 17th, 2024, Hasten Biopharmaceutical Limited Co., Ltd. (hereinafter as Hasten) announced that the clinical trial application (IND) for Lerodalcibep(hereinafter as the code：HST101), a novel third-generation PCSK9 inhibitor, has been approved by the Center for Drug Evaluation(CDE) of the National Medical Products Administration (NMPA) for the treatment of patients with hypercholesterolemia. The Company will accelerate domestic clinical trial preparations and initiate recruitment of subjects with hypercholesterolaemia.